NSE: PPLPHARMA · 29 October 2026
- Piramal Pharma has risen 16.04% over 2 trading sessions; today's move is -0.95%.
- Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of ₹2,617 crores in Q2 (up 28% year-on-year) and ₹4,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.
- Trading volume was 3.16 times the 20-day average daily volume.
Piramal Pharma share price: 16.04% rise over 2 trading sessions
Piramal Pharma Ltd. (PPLPHARMA) traded down 0.95% on Wednesday, closing at ₹230.60 after moving between an intraday high of ₹239.22 and a low of ₹225.68.
While the broader Indian equity market advanced, with the Nifty rising 1.05% and the Nifty Pharma sector index gaining 0.64%, Piramal Pharma experienced mild profit-taking. Wednesday's pullback follows a sharp multi-day rally that drove strong prior returns of 17.15% over the last one trading day, 19.28% over the past two sessions, and 18.26% over the preceding five trading days.
Company disclosures provide ongoing context regarding business performance, highlighted by the release of consolidated financial results for the quarter and half year ended September 30, 2026. Management reported robust H1 FY27 revenue of ₹4,887 crores, representing a 23% year-on-year increase, alongside a 72% surge in EBITDA to ₹669 crores and an upgraded full-year outlook. While these fundamental milestones supported recent upward momentum, Wednesday's price action appears largely consistent with consolidation and normal profit-taking following a steep prior advance.
2.56 crore shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 80.95 lakh shares (3.16 times). The five-day average daily volume was 2.55 crore shares. Separately, the NSE report for 28 October 2026 showed 1.86 crore shares delivered, representing 15.74% of that day’s traded volume. The same report recorded 710,974 trades.
The stock retreated slightly by 0.95% despite heavy cash volume reaching 3.16 times its 20-day average. This move follows an aggressive multi-day surge, including a 17.15% gain in the prior session, pointing to natural profit-taking and technical consolidation after sharp recent outperformance.
Latest Company Developments
Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of ₹2,617 crores in Q2 (up 28% year-on-year) and ₹4,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.
It establishes strong underlying operational momentum, improved capacity utilization, and upgraded growth expectations across all core business segments.
The company announced that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026, and will not be renewed. Piramal Pharma noted that revenue from this commission-based arrangement accounts for less than 5% of consolidated revenue and does not expect the non-renewal to materially impact its profitability or financial position.
It clarifies the financial impact of an ending distribution partnership, assuring investors that the transition will not materially affect earnings or guidance.
Piramal Pharma completed its previously announced transaction to acquire a controlling equity stake in Yapan Bio Private Limited, exercising its call option to strengthen its biologics and advanced therapeutic capabilities. This integration expands the company's specialized service offerings within the CDMO segment, particularly in high-growth biologics and process development.
It enhances the company's advanced technological capabilities in biologics, supporting long-term expansion within the high-value CDMO landscape.
a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2".
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.
The filing reported 27 MF/UTI holders.
What to Watch Next
- Execution of upgraded FY27 guidance targeting 19%-20% revenue growth
- Integration progress and revenue contribution from the Kenalog and Yapan Bio acquisitions
- Sustained order inflows and RFP activity within the CDMO segment
- Cash volume and delivery percentage trends relative to the 20-day average volume baseline
Other Dated Coverage
More Piramal Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Piramal Pharma company news?
Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of ₹2,617 crores in Q2 (up 28% year-on-year) and ₹4,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.
How strong was Piramal Pharma’s trading volume?
2.56 crore shares traded, 3.16 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.